Related Experiment Video

Updated: Aug 9, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

Stentless aortic valve replacement in elderly patients

S Gelsomino1, P Da Col, G Morocutti

  • 1Department of Cardiovascular Sciences, General Hospital 'S. Maria della Misericordia', Udine, Italy. sandrogelsomino@virgilio.it

Cardiovascular Surgery (London, England)
|June 5, 2002
PubMed

Insights

The Cryolife O'Brien (CLOB) stentless bioprosthesis demonstrated satisfactory clinical outcomes and hemodynamic improvements in elderly patients over seven years. This aortic valve substitute showed good survival rates and reduced left ventricular mass index.

Area of Science:

  • Cardiovascular Surgery
  • Bioprosthetic Heart Valves
  • Geriatric Cardiology

Background:

  • The Cryolife O'Brien (CLOB) stentless bioprosthesis is a type of aortic valve replacement.
  • Elderly patients (>75 years) often present with aortic valve disease requiring surgical intervention.
  • Long-term outcomes of bioprosthetic valves in this specific demographic are crucial for clinical decision-making.

Purpose of the Study:

  • To report the seven-year clinical and hemodynamic results of the CLOB stentless bioprosthesis.
  • To evaluate the efficacy and safety of the CLOB valve in elderly patients undergoing aortic valve implantation.
  • To assess changes in hemodynamic parameters and left ventricular remodeling post-implantation.

Main Methods:

  • A cohort of 36 patients aged over 75 years received a CLOB bioprosthesis in the aortic position between 1993 and 2000.
  • Serial echocardiograms were performed preoperatively, at discharge, and at regular intervals up to seven years post-implantation.
  • Clinical outcomes including survival and hemodynamic parameters were monitored throughout the follow-up period.

Main Results:

  • The 30-day mortality rate was 2.4% (1 patient).
  • Actuarial survival rates at seven years were high (94.8+/-2.0%).
  • Significant improvements were observed in hemodynamic function, including reduced gradients and increased effective orifice area index, along with a substantial reduction in left ventricular mass index.

Conclusions:

  • The CLOB stentless bioprosthesis proved to be a satisfactory valve substitute in elderly patients.
  • The study supports the use of the CLOB xenograft for aortic valve replacement in geriatric populations.
  • Positive long-term clinical and hemodynamic performance was demonstrated in this cohort.
Abstract

More Related Videos

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement08:50

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

Related Concept Videos

Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...